https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-results-report BiopharmaWatch en 2026-09-22T00:00:00.000Z Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 https://www.biopharmawatch.com/news/CUE/cue-biopharma-positive-results-cue-221-phase-2-study BiopharmaWatch en 2026-09-20T10:00:00.000Z Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria https://www.biopharmawatch.com/news/CAH/class-action-lawsuit-cardinal-health-expenses BiopharmaWatch en 2026-09-19T22:32:00.000Z Employment Law Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, Filed a Lawsuit Against Cardinal Health 414, LLC, for Alleged Failure to Reimburse Employees' Business Expenses https://www.biopharmawatch.com/news/OSCR/oscar-health-thrive-capital-stock-distribution BiopharmaWatch en 2026-09-19T00:31:00.000Z Oscar Health Announces Thrive Capital’s Completion of Oscar Health Common Stock Distribution to its Limited Partners https://www.biopharmawatch.com/news/VIVI/tempramed-reports-record-sales-2026 BiopharmaWatch en 2026-09-18T20:45:00.000Z TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue https://www.biopharmawatch.com/news/INM/inmed-pharmaceuticals-nasdaq-notification-shareholders-equity BiopharmaWatch en 2026-09-18T20:45:00.000Z InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance https://www.biopharmawatch.com/news/QGEN/qiagen-extraordinary-general-meeting-appointment-pratt BiopharmaWatch en 2026-09-18T20:05:00.000Z QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board https://www.biopharmawatch.com/news/CORT/corcept-chmp-recommends-approval-lifyorli BiopharmaWatch en 2026-09-18T18:58:00.000Z Riassunto: Corcept annuncia l'opinione del CHMP che raccomanda l'autorizzazione dell'UE all'immissione in commercio per Lifyorli® (relacorilant) https://www.biopharmawatch.com/news/CORT/corcept-chmp-positive-opinion-lifyorli BiopharmaWatch en 2026-09-18T18:58:00.000Z Samenvatting: Corcept kondigt positief CHMP-advies aan voor Europese markttoelating van Lifyorli® (Relacorilant) https://www.biopharmawatch.com/news/AEMD/aethlon-medical-investigation-merger-north-immunology BiopharmaWatch en 2026-09-18T18:00:00.000Z SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)